Analyst Breaks Down Bluebird Bio's Better-Than-Expected Clinical Results

By: via Benzinga
Wedbush analyst David Nierengarten maintains his Outperform rating and $95 target price on bluebird bio Inc (NASDAQ: BLUE), which ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.